MILAN — The weight loss and diabetes drug tirzepatide resolved metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, according to the results of the SYNERGY-NASH phase II study.
Among 190 participants with biopsy-confirmed MASH and fibrosis, the treatment regimen estimand showed resolution of MASH without worsening of fibrosis in 44% of patients in the once-weekly 5-mg tirzepatide group, 50% in the 10-mg group, and 62% in the 15-mg group compared with 10% in the placebo group (P
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/meetingcoverage/easl/110557
